Vertex Pharmaceuticals Incorporated VRTX NDXSPX

Healthcare · Biotechnology · United States

https://www.vrtx.com

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Market & Price

Market Cap

$113.59B

Current Price

$447.54

High / Low (52W)

$499.17 / $366.54

Beta

0.30

Valuation

Stock P/E

26.53

Industry PE

23.65

Forward P/E

20.84

PEG Ratio

1.68

Book Value

$76.18

Price to Book

5.87

P/S

9.30

EV/EBITDA

21.75

Dividend Yield

Profitability & Returns

ROCE

21.38%

ROE

24.20%

ROA

12.14%

Profit Margin

35.51%

Op Margin

38.13%

EPS (Latest Qtr)

$4.02

EPS (TTM)

$16.87

Balance Sheet & Liquidity

Debt/Equity

0.10

Quick Ratio

2.38

Current Ratio

3.02

Debt

$1.99B

Total Assets

$25.64B

Current Assets

$11.20B

Working Capital

$7.34B

Ownership

Promoter Holding

0.21%

Chg in Prom Hold

FII / Inst Holding

97.89%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

$108.33B

Total Revenue (TTM)

$12.22B

EBITDA

$4.98B

Free Cash Flow

$2.78B

Operating Cash Flow

$4.24B

Shares Outstanding

253.81M

Gross Margin

54.39%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

10.35%

Profit 5Y

5.97%

Revenue (YoY)

7.80%

Earnings (YoY)

61.40%

PROS

Strong return on equity of 24.2%.
Healthy ROCE of 21.4%.
Excellent profit margin of 35.5%.
Compounding revenue at 10.4% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VRTX Vertex Pharmaceuticals Incorporated NDXSPX	447.54	26.53	$113.59B	-	21.38%	24.20%	10.35%	5.97%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	714.72M	544.13M	578.16M	651.63M	640.80M	752.16M	784.53M	870.11M	858.43M	941.29M	949.83M	1.41B	1.52B	1.52B	1.54B	1.63B	1.72B	1.79B	1.98B	2.10B	2.20B	2.33B	2.37B	2.49B	2.48B	2.69B	2.65B	2.77B	-	2.77B	2.96B	3.08B	3.19B	2.99B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	363.00M	407.50M	414.80M	466.00M	392.80M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.41B	2.56B	2.66B	2.72B	2.59B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38B	1.40B	1.42B	1.59B	1.46B
Operating Income	-70.03M	-53.70M	-14.33M	3.35M	-18.73M	39.64M	270.84M	52.71M	-326.04M	125.74M	128.90M	172.88M	205.65M	127.72M	276.81M	269.96M	99.33M	551.47M	720.22M	718.03M	672.24M	745.79M	887.80M	-37.90M	1.05B	1.04B	1.11B	1.13B	779.00M	1.03B	1.04B	1.14B	-3.51B	1.12B	-	1.03B	1.15B	1.24B	1.13B	1.14B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.08B	1.34B	1.36B	1.39B	1.19B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.80M	3.00M	3.70M	3.30M	3.30M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	730.40M	1.28B	1.30B	1.33B	1.25B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84.10M	250.10M	215.90M	139.90M	221.50M
Net Income	-95.15M	-73.73M	-41.63M	-64.53M	-38.84M	32.95M	247.76M	18.00M	-102.95M	100.68M	210.26M	207.36M	128.75M	1.55B	268.63M	267.43M	57.52M	583.23M	602.75M	837.27M	667.43M	604.19M	653.10M	67.00M	851.90M	762.10M	810.50M	930.50M	699.80M	915.70M	1.04B	1.10B	-3.59B	1.05B	-	646.30M	1.03B	1.08B	1.19B	1.03B
Diluted EPS	-0.39	-	-0.17	-0.26	-0.16	0.13	0.99	0.07	-0.41	0.39	0.81	0.80	0.50	5.97	1.03	1.03	0.22	2.23	2.29	3.18	2.53	2.30	2.49	0.26	3.28	2.96	3.13	3.59	2.69	3.52	3.97	4.21	-13.92	4.01	-	2.49	3.99	4.20	4.65	4.02
R&D Expense	246.28M	310.18M	255.86M	271.01M	272.37M	248.45M	273.56M	289.45M	454.95M	306.66M	310.55M	337.53M	330.51M	437.88M	339.49M	379.09M	555.95M	480.01M	448.53M	420.93M	493.50M	466.58M	456.00M	1.41B	493.75M	603.10M	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	1.70B	2.49B	3.05B	4.16B	6.21B	-	8.93B	9.87B	11.02B	12.00B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.08B	1.26B	1.53B	1.65B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.85B	8.61B	9.49B	10.35B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.60B	4.83B	9.72B	5.80B
Operating Income	-462.71M	-614.01M	-696.08M	113.82M	46.73M	-610.01M	-692.41M	-466.88M	9.94M	123.24M	635.15M	1.20B	2.86B	-	4.25B	3.78B	-233.40M	4.55B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.44B	4.61B	486.30M	4.87B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.80M	44.10M	30.60M	13.30M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.23B	4.38B	248.50M	4.64B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	910.40M	760.20M	784.10M	690.00M
Net Income	-	-642.18M	-754.63M	29.57M	-107.03M	-445.03M	-738.55M	-556.33M	-112.05M	263.48M	2.10B	1.18B	2.71B	-	3.32B	3.62B	-535.60M	3.95B
Diluted EPS	-3.27	-3.71	-3.77	0.14	-0.50	-1.98	-3.14	-2.31	-0.46	1.04	8.09	4.51	10.29	-	12.82	13.89	-2.08	15.32
R&D Expense	516.91M	550.27M	637.42M	707.71M	765.90M	882.10M	855.51M	995.92M	1.05B	1.32B	1.42B	1.75B	1.83B	3.05B	-	-	-	-

Compounded Sales Growth

5 Years:	10.35%
1 Year:	7.80%

Compounded Profit Growth

5 Years:	5.97%
1 Year:	61.40%

Stock Price Performance

1 Year:	+1.24%
6 Months:	+4.12%
3 Months:	-9.92%
1 Month:	+5.74%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.96B	1.73B	2.20B	2.76B	2.32B	2.33B	2.50B	2.90B	3.55B	3.56B	6.25B	6.26B	8.32B	11.75B	13.43B	18.15B	22.73B	22.53B	25.64B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.23B	14.14B	9.60B	11.20B
Cash & Equivalents	355.66M	389.12M	446.66M	243.20M	475.32M	489.41M	569.30M	625.26M	714.77M	1.18B	1.67B	-	2.65B	-	3.11B	5.99B	6.79B	10.50B	10.37B	4.57B	5.08B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	460.60M	738.80M	1.21B	1.69B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.44B	1.56B	1.61B	2.05B
Total Liabilities	-	-	859.14M	1.22B	1.24B	1.52B	962.64M	1.24B	1.40B	1.56B	1.50B	-	1.81B	-	2.23B	3.06B	3.33B	4.24B	5.15B	6.12B	6.98B
Current Liabilities	-	-	284.88M	474.78M	392.35M	432.62M	397.83M	368.25M	506.17M	792.54M	807.26M	-	1.12B	-	1.33B	1.88B	2.14B	2.74B	3.55B	3.56B	3.86B
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	899.70M	808.40M	1.74B	2.03B
Total Equity	-	-	-	503.97M	786.84M	999.18M	1.36B	1.08B	939.97M	1.16B	2.03B	-	4.44B	-	6.09B	8.69B	10.10B	13.91B	17.58B	16.41B	18.67B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	257.01M	257.70M	256.94M	253.99M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-226.48M	-427.59M	-635.44M	143.74M	267.84M	-60.67M	-573.11M	-365.43M	236.10M	844.94M	1.27B	1.57B	3.25B	-	4.13B	3.54B	-492.60M	3.63B
Investing Cash Flow	-360.65M	-508.73M	7.30M	-	-	-	-	268.86M	51.24M	-483.33M	-202.16M	-1.24B	99.40M	-	-321.10M	-3.14B	-3.77B	-945.40M
Financing Cash Flow	620.74M	999.01M	425.06M	-	-	-	-	188.92M	133.27M	68.40M	-71.22M	126.80M	-505.30M	-	-67.70M	-562.20M	-1.49B	-2.26B
Capital Expenditure	-32.18M	-23.50M	-38.05M	-34.59M	-71.14M	-51.39M	-51.20M	-45.30M	-56.56M	-99.42M	-95.45M	-75.40M	-259.80M	-	-204.70M	-258.40M	-485.40M	-437.60M
Free Cash Flow	-258.66M	-451.08M	-673.50M	109.14M	196.70M	-112.06M	-624.31M	-410.73M	179.54M	745.52M	1.17B	1.49B	2.99B	-	3.93B	3.28B	-978.00M	3.19B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.74B	-166.60M	-5.76B	424.70M
Share Buybacks	-	-	-	-	-	-	-	-	0	0	350.04M	186.00M	539.10M	1.43B	0	427.60M	1.18B	2.02B

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.9%	87.2%	86.1%	86.2%
Operating Margin %	-	-	-	-	-	-	-	-	0.6%	5.0%	20.8%	28.8%	46.0%	-	47.6%	38.3%	-2.1%	37.9%
Net Margin %	-	-	-	-	-	-	-	-	-6.6%	10.6%	68.8%	28.3%	43.7%	-	37.2%	36.7%	-4.9%	32.9%
ROE %	-	-	-149.7%	3.8%	-10.7%	-32.8%	-68.7%	-59.2%	-9.7%	13.0%	47.3%	19.3%	31.2%	-	23.9%	20.6%	-3.3%	21.2%
ROCE %	-	-36.8%	-55.7%	6.3%	2.0%	-31.8%	-35.2%	-23.4%	0.5%	4.5%	12.4%	17.1%	28.9%	-	27.6%	19.7%	-1.2%	20.9%

Shareholding Pattern

Insiders

0.21%

Institutions

97.89%

Public Float

98.09%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Capital World Investors	10.00%	25.37M	$11.35B
2	Blackrock Inc.	9.44%	23.97M	$10.73B
3	Capital Research Global Investors	8.32%	21.13M	$9.45B
4	Vanguard Capital Management LLC	6.51%	16.51M	$7.39B
5	State Street Corporation	4.62%	11.73M	$5.25B
6	JPMORGAN CHASE & CO	2.77%	7.03M	$3.15B
7	Geode Capital Management, LLC	2.42%	6.14M	$2.75B
8	Vanguard Portfolio Management LLC	2.03%	5.15M	$2.30B
9	Capital International Investors	2.02%	5.13M	$2.29B
10	LOOMIS SAYLES & CO L P	1.58%	4.00M	$1.79B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VRTX

No recent headlines available.

VRTX · Healthcare